Rapamycinwasadministeredinfoodtogeneticallyheterogeneousmicefromtheageof9monthsandproducedsignifi-cantincreasesinlifespan,includingmaximumlifespan,ateachofthreetestsites.Mediansurvivalwasextendedbyan averageof10%inmalesand18%infemales.Rapamycinattenuatedage-associateddeclineinspontaneousactivityin malesbutnotinfemales.Causesofdeathweresimilarincontrolandrapamycin-treatedmice.Resveratrol(at300and 1200ppmfood)andsimvastatin(12and120ppm)didnothavesignificanteffectsonsurvivalinmaleorfemalemice. Furtherevaluationofrapamycin'seffectsonmiceislikelytohelpdelineatetheroleofthemammaliantargetofrapamycincomplexesintheregulationofagingrateandage-dependentdiseasesandmayhelptoguideasearchfordrugsthat retardsomeorallofthediseasesofaging.
A
GENTSthatcanextendthe lifespanofmiceareof interestfortworeasons:theycanprovidenewmodels of delayed aging to teach us more about what controls agingrateandhowagingleadstodisease;andinaddition, they serve as a first step toward eventual development of pharmaceuticals to slow aging and retard diseases in humans. The National Institute on Aging Intervention Testingprogram(ITP)haspreviouslyreportedsignificant increases in life span caused by aspirin and nordihydroguaiareticacid inmalemice(1)andbyrapamycinin bothmaleandfemalemice (2) .ThedesignoftheITP(3) emphasizestheuseofgeneticallyheterogeneousmiceto mitigate against idiosyncrasies that can complicate interpretationofdatafromasingleinbredorF1hybridstock andincludesparallelreplicationofprotocolsatthreesites, the University of Texas (UT), University of Michigan (UM), and The Jackson Laboratory (TJL), with standard operatingprotocolsthatattempttoreproducekeyelements of the environmental conditions at each site. Sufficient numbers of mice are used in each yearly cohort to give morethan80%powertodetectanincreaseordecreaseof 10%inmeanlifespan,withrespecttocontrolsofthesame sex,evenifonlytwoofthethreesitescancontributedata tothepooledanalysis.
Our previous report (2) showed significant increases in longevityinmaleandfemalemiceexposedtorapamycin, aninhibitorofthemammaliantargetofrapamycin(mTOR) proteinkinase,from20monthsofage(Cohort2005).The effects were seen at each site evaluated independently. Rapamycinledtoanincreaseinthefractionofmicealiveat the90thpercentilesurvivalage,takenasanindexofmaximallifespan.Thereportalsopresentedpreliminaryresults fromaseparategroupofmice(Cohort2006)thathadreceived rapamycin from 9 months of age, and which had reachedthemediansurvivalageatthetimethedatawere analyzed.Inthecurrentreport,wenowpresentananalysis of the completed data set from the mice in Cohort 2006, showingextensionofmedianandmaximallifespaninmice given rapamycin from 9 months of age, and comparing the effect of rapamycin with two other drugs of interest, resveratrol,apolyphenolwithpleiotropiceffects,andsimvastatin, a representative statin that in humans modulates lipid profiles by lowering low-density lipoproteins (LDL cholesterol).
Methods

Mice
The test populations were produced by a cross between twodifferentF1parents:(BALB/cByJ×C57BL/6J)F1moth-ers(JAXstock100009)and(C3H/HeJ×DBA/2J)F1fathers (JAXstock100004).ThesewerereferredtoasUM-HET3, reflectingtheiroriginaldevelopmentattheUMasagenetically heterogeneous population for gene mapping. Each mouseinthetestpopulationwasthusgeneticallyunique,but sharedhalfofits(nuclear)genomewitheveryothermouse. Micewerebredoveraperiodof6-8monthsateachsite,and eachcageofweanlingswasassignedtooneofthetestgroups (controlordrugtreatment)byuseofarandomnumbertable. Awrittenprotocolwasusedbyeachsitethatincludeddetails ofhusbandry,includingsourceandamountofbedding;cage ventilation;frequencyofcagechanging;insertionofelectronic identification devices at age 42 days; and other details of husbandry. Each colony was tested for pathogen status as described (3) Asreportedpreviously (2) ,thethreetestsitesdiffered in the source of mouse chow provided to the mothers of the test mice and also in the source of mouse chow providedtothetestmicebeforetheintroductionofdrugcontainingfood.Althougheachofthesedietsconformed totheNationalInstitutesofHealth-31standard,itispossiblethatthesevariationsinearlydiethistorymayhave contributedtothedifferencesamongsitesinbodyweight trajectories, with both male and female mice at UM lighterinweightthanmiceattheothertwosites(3),and perhaps contributed as well to intersite differences in survivalrates. Table 1 lists the agents used for Cohort 2006, together withthesuppliers,ageofinitialexposuretothedrug,and the doses used.As in our previous report (2) , rapamycin was given in an encapsulated form that is water-soluble onlyinnonacidicconditions,toprotectitfromreleaseand degradationinthestomach beforeitsentryintothesmall intestine. Note:Calculationofdosepermouseanddoseperkgmousebodyweightperdayassumethatanaveragemouseweighs30gandconsumes5gofmousediet perday.Therapamycinwasgiveninencapsulatedformasdescribedin (2) .
Activity Testing
Approximately100controlmice(halfmales)ateachsite, plus approximately 50 mice in each drug-exposed group, wereevaluatedat7monthsandthen(forsurvivors)again at 18 months for several indices of spontaneous in-cage activity, using a computer-controlled Micromax apparatus (Accuscan,Columbus,OH).Micewereremovedfromtheir homecageatapproximately8:00amandplacedindividuallyin freshcagesinthetestingroom.Laserlight(atalowintensity,whichdoesnotharmthemice)wasdetectedbysensors outsidethecagetocountthenumberoftimesinwhicha mouseinterruptsthelaserbeam.Themicewereleftinthe chamberfor50 hours,withfreeaccesstofoodandwater and the same light-dark cycle to which they were accustomedintheirhomecages.Theanalysissystem provided measures of total number of beam breaks over arbitrarily smalltimewindows;wetypicallytabulatedthedatausing 1-hourwindows.Thedatawerealsoanalyzedtorevealthe proportion of activity that took place with lights on or off, and the proportion of activity attributable to stereotypicmovement(ie,movementinplace)versusambulatory movement.Thedataatage7monthsprovidedabaselinefor eachmousetopermitcalculationof"changescores"atthe laterage,whicharetakenasthebestestimateofageeffect foreachindividualmouse.Thetestedmicewereincludedin thepopulationsevaluatedforlongevityeffects.
Necropsies and Histopathology
Eachmouseinthestudywasexaminedatleastonceeach day.Thedateofdeathwasrecordedforeachmousefound dead.Inothercases, micethatweredeemedtobesosick thatsurvivalformorethananother48hoursisconsidered unlikelywereeuthanized;thedateofeuthanasiaistakenas thebestestimateofthedateofnaturaldeath.Thisdecision ismadebasedonasymptomchecklistthatisusedateach site. Specifically, a mouse was considered severely moribundifitexhibitedmorethanoneofthefollowingclinical signs:(a)inabilitytoeatortodrink;(b)severelethargy,as indicatedbyreluctancetomovewhengentlyproddedwith aforceps;(c)severebalanceorgaitdisturbance;(d)rapid weightlossoveraperiodof1weekormore;or(e)anulceratedorbleedingtumor.Thissymptomchecklist complied withtherulesofeachofthethreeinstitutionsrelatedtohumane treatment of mice and was also consistent with the experimentalgoals.Eachmousefounddead,oreuthanized, was retained for possible inclusion in a necropsy study. Incisionsweremadeinthecranium,thorax,andabdomen, andtheentirebodywasimmersedin10%neutralbuffered formalin and kept in a sealed container before transfer to thepathologyunitafteranintervalofupto4years.
AmongthemiceinCohort2006,110wereevaluatedfor end-of-lifepathology:approximately9malesand10females, fromeachofthethreesites,fromthecontrolandrapamycintreatedpopulations,selectedfromeachsitebyuseofarandom numbertable.Causeofdeathwasinferred,wherepossible, based on gross evaluation, followed by histopathologic examinationofastandardsetoftissuesfromeachmousebyan experiencedveterinarypathologist.Tumorsweredeemedthe cause of death based on tumor type, size, number, and distribution. Cause of death for mice with inflammatory or degenerativelesionswasbasedonthelocationandseverityof the lesions and the likelihood that such lesions were severe enoughtocausemorbidityandmortality.Manyanimalshad smalllocalizedtumorsandvariousdegenerativelesions,which weredeemedunlikelytohavecontributedtotheirdeath.
Statistical Methods
For each question of interest, the initial analysis evaluatedthenullhypothesisthateachofthesixtreatmentgroups (rapamycin,twodosesofsimvastatin,twodosesofresveratrol, and controls) had the same level of the test variable. Theseinitialanalysespooleddatafromallthreesitestoprovide maximal statistical power. Males and females were evaluatedseparately.Forsurvivaldata,theinitialcomparisonusedthelog-ranktest;forweightandactivitydata,the initialtestwasbyanalysisofvariance(ANOVA).Whenthe initial test refuted the null hypothesis at p = .05, we then followedupwithtestscomparingeachdrug-treatedgroup, individually,tothecontrolpopulation,againpoolingacross sites and for each gender separately. Log-rank tests for effectsonsurvivalincludedmiceremovedfromthestudy (describedabove),aslosttofollow-upattheageofremoval; these mice were not included in estimates of median life spannorincalculationsof90thpercentilesurvival.
Results
We have previously reported (2) that male and female UM-HET3micegivenrapamycinfrom20monthsofage had longer life spans than controls, and that rapamycin administered from 9 months of age led to lower mortality whenevaluatedatthemedianageforcontrolsurvival.Atthe currentanalysispoint,thegroupsofmiceexposedtorapamycin from9months(Cohort2006)hadreachedthepointwhere 99.8%oftheanimalsdied,andnoanimalremainedaliveat an age younger than the 99th percentile for control group survival.Rapamycinwasfoundtoleadtoimprovedsurvival in both males and females when pooling across test sites (Figure1),andtosignificanteffectsateachtestsiteconsideredseparately(Figure2).Table2presentscalculatedvalues formedianageand90thpercentileageforeachgroup.For males,rapamycinledtoanincreaseof10%inmedianage, averagedacrossthethreesites,andanincreaseof16%inthe 90thpercentileage.Forfemales,thecorrespondingvalues were18%formedian,and13%for90thpercentileages.
Inferences about maximal survival, that is, survival to exceptional ages were evaluated by the test of Wang and colleagues (4) and found to be significant both for the pooled data sets and for each combination of gender and site considered separately. For males, 3% of the controls and 24% of the rapamycin-treated mice were alive at the ageof90%mortality.Forfemales,3%ofcontrolsand25% ofrapamycin-treatedmicewerealiveatthe90thpercentile point of the joint survival distribution. By Fisher's exact test,theseproportionsdifferatp<.001forthepooleddis-tributionsandformalesandfemalesateachsiteconsidered individually,exceptthatp<.002forthemalesandfemales atTJL.Weconcludethatrapamycinincreaseslifespanin maleandfemalemiceofageneticallyheterogeneousstock anddoessoreproduciblyateachofthethreetestsites.
Figure3showscalculatedmortalityrisksasafunctionof age for control and rapamycin groups, combining across sites and gender; the left panel shows the raw mortality plotsfordeathspooledinto2-weekintervals,andtheright panelshowsthesmoothedplotswithfittedGompertzlines superimposed.Visualinspectionsuggestsaright-shiftinthe mortality trajectory caused by rapamycin treatment such thattreatedanimalsexperiencearoughly20-weekdelayin the onset of senescent mortality. Rapamycin treated mice alsohavesignificantlylowerinterceptvalues(2.3×10 −5 vs 2.6×10 −5 forcontrols).Theseobservationswouldbeconsistentwiththeideathatrapamycinactsrapidlytoreduce age-specific mortality, but the small number of observed deathsimmediatelyfollowingtreatmentmakeitimpossible totestthehypothesisdirectly.Althoughthereisevidencethat rapamycintreatmentalsoalterstherateofchangeinmortality withage(0.0050vs0.0058inrapamycinandcontrolcohorts, respectively), this result should be interpreted with caution becausesignificantdifferencesinthesizesoftheexperimental andcontrolcohortsmaydifferentiallybiasearly-lifemortality estimatesandskewmeasuresofmortalityslopes(5). The two data sets were not produced simultaneously, but theydorepresentworkdoneusingthesameconditionsof drug preparation, diet, water source, housing, and genetic stocksatthesamethreesites,withonlya1yearlagbetween startdates.Formalemice,startingrapamycinat9months ratherthanat20monthsdidnotleadtoanyimprovementin survival;thetwocohortswerenotsignificantlydifferentby log-ranktest,atp=.74.Forfemalemice,thereisasuggestion that earlier exposure to rapamycin may have led to someslightdeclineinmortalityriskbefore~1000daysof age,butthelog-ranktestisnotsignificant(p=0.31).The Wilcoxon-Breslow test, which does not assume that the differenceinriskbetweenthetestgroupsisconstantatall ages and which gives more weight to earlier deaths, was alsononsignificantforfemales,atp=0.09(twotailed).It willbeofinteresttodetermineifgenderdifferencesinrapamycin effect are seen using higher or lower doses of this drug,andtoseeifmalesandfemalesdifferinthebiochemicalorphysiologicalresponsestorapamycintreatment.
Figure5showsmeanbodyweightvaluesforcontroland drug-treatedmice(Cohort2006)foreachsex.Micegiven rapamycinfrom9monthsofagearelighterinweightthan controls;theeffectissignificantformalesat12,18,and24 monthsofage,butinfemalesonlyat18months.Theeffect inmalesislessthan10%ofthecontrolweightatallages, andlessthan6%infemales.
OthermiceinCohort2006wereexposedeithertosimv-astatin(at12or120ppm)ortoresveratrol(at300or1200 ppm)fromtheageof10or12months,respectively.Figure6 shows the survival curves, for data pooled across sites, at eachcombinationofdoseandsex.Neitherofthesedrugs affectedsurvivalateitherhighorlowdosesineithersex. Nor did either of the drugs lead to a significant improvementinsurvivalatanyoneofthetestsitesconsideredseparately (not shown). The doses of resveratrol used were twofoldandeightfoldhigherthanthoseusedforthestudy showing a beneficial effect of resveratrol on median survivalinC57BL/6miceonahigh-fatdiet (6 TJLmale  UMmale  UTmale  Meanmale  TJLfemale  UMfemale  UTfemale  Meanfemale   Control,median  800  851  780  889  891  843  Rapamycin,median  841  932  888  1077  1008  1006  %Change  5  10  14  10  21  13  19  18  Control,P90 1 Table 3 summarizesthecauseofdeathdiagnoses.Themostcommon causes of death among controls were lymphoma, hemangiosarcoma, and lung carcinoma, which together accountedfor70%ofthecases.Thesethreediagnoseswere also the most common in the rapamycin-treated mice, accountingfor66%ofthediagnoses.Lungcarcinomawas somewhatmorecommonamongtherapamycinmice(34% vs 15% for controls, p = .04), and hemangiosarcoma and lymphomawereslightlymorecommonamongcontrols(not significant:p=0.33andp=.1,respectively).Therewereno significant differences between controls and rapamycintreatedmiceintheincidenceofadrenaldegeneration(19% of rapamycin mice, vs 7% of controls, p = .07), adrenal hyperplasia,myocardialdegeneration,myocardialfibrosis, skeletalatrophy,pulmonaryadenoma,pulmonaryadenocar- cinoma (fatal combined with nonfatal cases), endometrial hyperplasia (in females), or testicular atrophy (in males). Elevenpercentoftherapamycinmice,and7%ofthecon-trols had a non-neoplastic illness as the likely cause of death. Table 3 also shows the mean age at death for each ofthediseasesfoundinatleasttwomiceofeachkind.Althoughtheamountofdataislimited,thereisnoevidenceto suggestthatrapamycinacceleratesanyspecificformofneoplasia.Insummary,rapamycin,thoughitdelayeddeath,did notleadtoadramaticchangeintherangeoflethalornonlethalillnessesfoundamongthesemiceoncetheydiddie.
Asubsetofmiceineachtestgroupwastestedat7months of age for spontaneous activity in a standard mouse cage overa50-hourperiod.Mostoftheseindividualswerethen retested at 18 months to provide a change score, corresponding to the difference in activity at the two ages for eachmouse.Thisageeffectwassignificantinbothmales and females, but the effect differed greatly in magnitude fromsitetosite.Wethereforeusedatwo-factor ANOVA (siteand treatmentaspredictorsofactivitychangescore), takingthesignificanceofthetreatmenteffectasourindicatorofwhetherinterventionhadaneffectonactivitylevels. This treatment effect was significant for males (p = .007) butnotforfemales(p=.42).Includinganinteractionterm (Site×Treatment)inthe ANOVAdidnotalterthesignificance of the treatment effect in either sex. We therefore evaluatedeffectsofeachagent,comparedwithcontrols,in malesonly.Onlyrapamycinhadasignificanteffectontotal activitychangescores(p=.003).Becausethechangescores were not normally distributed, we also used the nonparametricWilcoxonranksumtest,andagainfoundasignificant effect for rapamycin compared with controls (p = .003). aging from 7 to 18 months diminishes this ratio to 0.42 (p=.0005bypairedt test);theamountofdaytimeactivity diminishes more rapidly than nighttime activity over this 11-month period.The age effect, for males, is seen at all threesites,with valuesof0.03,0.06,and0.05forTJL,UM, andUT,respectively.Rapamycindidnothaveasignificant effectonthisday:totalratioinpooledmalesoratanyone ofthetestsites,buttheageeffectwassignificantlydiminished by resveratrol at both the high dose (p = .003 for pooledmales,andp=.02and.01forTJLandUM,respectively)andatthelowdoseforthisagent(p=.03forpooled males).Neitherdoseofsimvastatinhadasignificanteffect on the day:total ratio. Age also diminished the day:total ratioinfemales,butnottoasignificantextentinthepooled dataset.Ofthedrugstested,onlyhigh-doseresveratrolhad asignificanteffectontheday:totalratioinfemales(p=.04 inpooledfemales).
Discussion
ThemTOR enzyme,aproteinkinase,helpstointegrate cellularactivitiesinresponsestonutrients,stress,andextracellularsignals,includinghormonesandlocallyproduced growthfactors (7, 8) .InvolvementofmTORinregulationof agingwassuggestedbyevidencethatimpairmentofmTOR activity in flies (9), worms (10, 11) , and yeast (12) could leadtolifespanextension,andbyobservationsthatmTOR functionwaslowerinseveralmousemodelsofslowaging, including data on dwarf mice (13) and in mice subjected tocaloricrestriction (14) .Ourpreviousreport(2)wasconsistent with these earlier studies showing that rapamycin treatment initiated at 20 months of age led to significant increaseinlifespaninbothmaleandfemalemiceateach ofthreetestsites.Similaritiesbetweentheeffectsofrapamycintreatmentandthoseofacalorie-restrictiondiethave supportedspeculation (7, 15) thattheabilityofcalorie-restriction toextendrodentlifespanmaybemediatedatleastpartlyby downregulationofmTORinoneormoretissues.Because ribosomal S6 protein kinase (S6K) is among the major targetsofmTORaction,areportthatdeletionofthegene forS6K1increaseslifespaninfemalemice(16)andretards ageeffectsonbone,immunity,andmotorfunctionprovides strongjustificationforadditionalworkonmTORpathways asmodulatorsofagingandlate-lifeillnesses. Ournewdataextendourpreviousobservationsinseveral ways.Theyprovideafullyindependentreplicationtoshow that rapamycin can extend mouse life span in males and females,andtheyshowthattheeffectdoesnotdependon theageatwhichdrugexposureisbegun,atleastbetween 9and20monthsofage.Oursurrogateformaximum life span,thatis,theproportionofmiceineachpopulationalive atthe90thpercentileage,wassignificantlyaffectedbyrapamycinintheCohort2006populationateachofthethree sites.Thedataonspontaneousactivitylevelssuggestthat rapamycinmayhaveretardedtheeffectsofagingonactivity, althoughtheeffectseemsrestrictedtomales,andinterpretationiscomplicatedbysite-to-sitevariationsinthesizeofthe ageeffect.Whenrapamycinisinitiatedat9monthsofage,it leadstoadeclineintherateofweightgain,whichisapparent inmalesby12monthsofageandinfemalesby18months. Thisisconsistentwiththeknowneffectsofrapamycinonproteintranslationandcellsize.Thesizeofthiseffectissmaller thanthattypicallyseeninmicesubjectedtocalorie-restriction dietssufficienttoextendlifespan,andfurtherstudieswillbe needed to determine whether rapamycin effects body mass viachangesinleanmass,levelofadiposity,orboth.Similarly, itwillbeinformativetoseeifrapamycinhasbeneficialeffects onmicesubjectedtoacalorie-restrictiondiet. Acomparisonofsurvivalresultsbetweenmiceexposed torapamycinfrom9monthsofage(thisreport),andthose inourpreviousstudyusingrapamycinfrom20monthson-ward,showednosignificantadvantageofstartingtheagent attheearlierage.Interpretationiscomplicated,however,by thetrend(two-tailedp=.09byWilcoxon-Breslowtest)for improved survival in female mice and by differences in midlife diet formulations at UT and UM in the original study (2) .Inferencesbasedoncomparisonofnonsimultaneousdatasetshavewell-knowndisadvantages.Inprinciple, however,anagentthatslowedtheoverallprocessofaging wouldbeexpectedtohaveastrongereffectifstartedata relativelyearlyage.Thus,iflaterworkconfirmsthatrapamycintreatmentstartinginlaterlifeisfullyaseffectiveas treatment started early in adult life, this could be taken asevidencethattheagentisnotmodulatingagingsomuchas limitingthepaceof,orvulnerabilityto,latelifeillnesses, such as the neoplastic diseases that lead to most of the Figure7 . Ageeffectsontotalactivityinmalemice,comparingcontrolto rapamycin-treatedmice.They-axisshowschangescore,calculatedas(activity at18months)minus(activityat7monthsinthesamemouse TheprincipalcauseofdeathofUM-HET3iscancer,with the largest proportion of deaths attributable to lymphoma (2) .Therefore,itispossiblethatrapamycinmayextendlife spanatleastinpartthroughdelayorpreventionofcancer.In fact,inhibitorsofmTORareunderbothpreclinicalandclinicalinvestigationfortreatmentofcancer (18) (19) (20) (21) (22) (23) .Arapidly expanding list of rapamycin analogs (rapalogs) are being usedfortreatmentofcancer (19, 20) .Usedalone,rapalogs havehadmixedresults.Overall,theresponsesofpatientsto treatmenthavebeenmodest.However,insomecancerssuch aslymphoma,forexample,rapalogsusedasasingleagent haveshownencouragingresponserates.Inothers,however, theresponseratesarelessimpressive,withtheclinicaloutcome being to stabilize the disease rather than producing tumorregression (19) .PlannedstudiesintheITPwilldeterminetheextenttowhichthelife-extendingeffectsofrapamycinarerelatedtothedelayorpreventionofcancer.
OneofthemajorgoalsoftheITPistoevaluatepossible anti-aging effects of drugs that have shown promising effectsininvertebratemodels,incellcultureassaysthoughtto berelevanttotheagingprocess,orinrodentstudies (24) . Resveratrolwaschosenforstudybecauseofpromisingdata (25) fromanimalmodelsofcancer,heartdisease,stroke,and immunityandbecauseofdatasuggestingitcouldactivate sirtuins,aclassofproteindeacetylasesimplicatedincontrol oflifespaninyeast (26) ,flies (27) ,andworms (28) .Resveratrolat22mg/kgbodyweightperdayhadalsobeenshown toimprovethemediansurvivalofmaleC57BL/6Niamice subjectedfrom1yearofagetoahigh-fatdiet(with60%of caloriccontentasfat) (6) .Asubsequentreport (29) ,based onthecompletesurvivalcurvewithterminalnecropsydata, showedthatimprovedsurvivalofmicegivenresveratrolon the high-fatdietcouldbeattributedtoreductionofdeaths duetolipidaccumulationintheliverandsubsequentpulmonary congestion and edema. Mice given resveratrol on a standarddiet(AIN-93G)werefoundtoberelativelyresistant to age effects on aortic elasticity, cataract formation, bonemineralization,andgeneexpressionpatterns,butdid notshowanysurvivaladvantageovercontrols (29) .Ourresveratroldatathusservetoconfirmtheabsenceofanyeffect ofthisagentonmouselifespan,usingdosestwo-toeightfoldhigherthanthedosestudiedbyPearsonandcolleagues and using genetically heterogeneous mice of both sexes rather than male C57BL/6Nia mice alone. Several groups havereportedthatresveratrolisabletoincreaselifespanin Drosophila (30, 31) andCaenorhabditis elegans (30, 32, 33) , and a short-lived species of fish (34), though others have reportedthatthisagentdidnotincrease lifespanineither of the first two species (35) . In addition, the idea that thepharmacologicaleffectsofresveratrolaremediatedby directactivationofSIRT1hasbeenchallengedbydatasug-gesting that the agent does not activate the deacetylase activityofSIRT1invitrowhenenzymefunctionisevalu-atedusingnaturalsubstratesratherthanthefluorochromeconjugated substrates used in earlier experiments (36) (37) (38) Follow-upstudiesarenowunderwaytoaddressseveralof the issues and opportunities raised by these findings. One suchstudywillevaluatedosesofrapamycinbothhigherand lowerthanthedoseusedfortheinitiallongevitystudies:It isunlikelythattheinitialdoseselectedwillturnouttohave been optimal for life span extension, but it is difficult to guesswhethertheoptimaldosewillprovetobehigheror lower. Cross-sectional histopathology will help to identify earlierstagesofcommonage-dependentillnesses,including thosethatdonottypicallyleadtodeath,toprovideamore comprehensivepictureofwhichformsofpathophysiology areretarded(or,perhaps,accelerated)bythedrug.Studiesof multipleage-dependentphysiologicaloutcomeswillalsobe included. These physiological endpoints, along with the cross-sectional histopathology, will help to show whether thelifespanimprovementrepresentsmerelyaglobalinhibition of neoplastic disease, or rather an authentic antiaging effectthatincludesanticancerprotectionasjustoneamong manyconsequences.Thefollow-upstudieswillalsoevaluate biochemical changes in multiple tissues, to see which tissuesshowlong-termandshort-terminhibitionofmTOR andmodulationofmTOR-dependentcellularfeedbackcircuitry.Althoughitisplausibletoassumethattheeffectsof rapamycinonhealthandlongevityreflectsimplydownregulation of mTOR and mTOR-dependent downstream pathways, it is also possible that some of the physiological effectsarecausedbycompensatoryupregulationofenzymes involved in mTOR-dependent feedback mechanisms. It is equallyplausiblethatthehealthbenefitsofrapamycinprincipallyreflectachangeinoneorafewcelltypes,perhaps locatedinhypothalamus,vascularendothelium,ahormoneproducingcelltype,orastemcellcompartment,whosebeneficialeffectsonothercelltypesareindependentofthelevel ofmTORfunctioninthedownstreamtargettissues.Evaluationofrapamycineffectsonrodentmodelsofspecificdiseases is likely to be very informative in this regard. For example,tworecentstudieshaveevaluatedrapamycineffects ondifferentmousemodelsofAlzheimer'sdiseaseusingthe samerapamycinpreparationusedintheITPstudies.Each study found that rapamycin rescued memory deficits and slowedpathologicalmanifestationsintheseneurodegenerativemodels (48, 49) .Analysisofeffectsonotherrodent(and perhaps canine) models of late-life diseases should prove equallyinformative.Itwillalsobehelpfultolearnifrapamycincanfurtherimprovethelongevitybenefitsproduced byspecificmutations(50)ordiets(51)orotherdrugs(1). Researchershavelearnedmuchaboutthebiologyofaging bystudiesofcaloricrestrictionandofantiagingmutations, andtheadventofeffectiveantiagingdrugsshouldprovide additionalleveragefornewworkonthefactorsthattimethe coordinatedappearanceofage-relateddecline.Inaddition, work on antiaging interventions holds more promise for the eventual development of protective medicines than approaches that entail modification of germline genes or lifelongcompliancewithextremedietaryrestrictions.
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